<DOC>
	<DOC>NCT02061709</DOC>
	<brief_summary>The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at reducing allergy symptoms in people who suffer from allergy to Ragweed pollen</brief_summary>
	<brief_title>Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>Male or female, aged 1865 years. Reliable history consistent with moderate to severe rhinoconjunctivitis on exposure to ragweed for at least the previous two seasons. Minimum qualifying rhinoconjunctivitis symptom scores Ragweedspecific Immunoglobulin E (IgE) &gt; 0.70 kU/L. Subjects with a history of ragweed pollen induced asthma A history of anaphylaxis to ragweed allergen. FEV1 &lt; 80 % of predicted. Subjects who cannot tolerate Baseline Challenge in the EEC. Subjects for whom administration of epinephrine is contraindicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension). History of immunopathological diseases (e.g. multiple sclerosis) that in the opinion of the Investigator or the Sponsor could interfere with the results obtained from the study. A history of severe drug allergy, severe angioedema or anaphylactic reaction to food. A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Seasonal</keyword>
	<keyword>Ragweed</keyword>
	<keyword>Allergy</keyword>
</DOC>